Edesa Biotech, Inc.

Edesa Biotech, Inc. company information, Employees & Contact Information

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

Company Details

Employees
22
Founded
-
Address
100 Spy Court, Markham,on L3r 5h6,canada
Phone
(905)-475 1234
Email
in****@****ech.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Markham, ON
Looking for a particular Edesa Biotech, Inc. employee's phone or email?

Edesa Biotech, Inc. Questions

News

Edesa Biotech Announces Positive Phase 3 Results for Paridiprubart in Treating Acute Respiratory Distress Syndrome, Showing Significant Reduction in Mortality - Quiver Quantitative

Edesa Biotech Announces Positive Phase 3 Results for Paridiprubart in Treating Acute Respiratory Distress Syndrome, Showing Significant Reduction in Mortality Quiver Quantitative

Edesa Biotech (Nasdaq: EDSA) posts Phase 3 ARDS results: 25% lower death risk, recovery - Stock Titan

Edesa Biotech (Nasdaq: EDSA) posts Phase 3 ARDS results: 25% lower death risk, recovery Stock Titan

Edesa Biotech Amends Agreement with Canadian Government - TipRanks

Edesa Biotech Amends Agreement with Canadian Government TipRanks

Edesa's New Vitiligo Drug Manufacturing Progress Signals Path to Phase 2 Trials as Q3 Financials Hold Steady - Stock Titan

Edesa's New Vitiligo Drug Manufacturing Progress Signals Path to Phase 2 Trials as Q3 Financials Hold Steady Stock Titan

Positive Signs As Multiple Insiders Buy Edesa Biotech Stock - Yahoo Finance

Positive Signs As Multiple Insiders Buy Edesa Biotech Stock Yahoo Finance

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results - GlobeNewswire

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results GlobeNewswire

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results - GlobeNewswire

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results GlobeNewswire

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewswire

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules GlobeNewswire

EDSA Stock Price and Chart — NASDAQ:EDSA - TradingView

EDSA Stock Price and Chart — NASDAQ:EDSA TradingView

Edesa Biotech Announces Chief Financial Officer Transition - GlobeNewswire

Edesa Biotech Announces Chief Financial Officer Transition GlobeNewswire

EDSA - Edesa Biotech Inc Latest Stock News & Market Updates - Stock Titan

EDSA - Edesa Biotech Inc Latest Stock News & Market Updates Stock Titan

Edesa Biotech’s Founder Makes Strategic Investment in the Company - GlobeNewswire

Edesa Biotech’s Founder Makes Strategic Investment in the Company GlobeNewswire

Top Edesa Biotech, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant